INmune Bio Q3 2023 Earnings Report $5.98 +0.02 (+0.34%) As of 10:39 AM Eastern Earnings HistoryForecast INmune Bio EPS ResultsActual EPS-$0.48Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AINmune Bio Revenue ResultsActual Revenue$0.04 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AINmune Bio Announcement DetailsQuarterQ3 2023Date11/1/2023TimeN/AConference Call ResourcesPress ReleaseINMB Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by INmune Bio Earnings HeadlinesINmune Bio treatment of epidermolysis bullosa receives FDA orphan designationJanuary 7, 2025 | markets.businessinsider.comINmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025January 2, 2025 | seekingalpha.comThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…January 15, 2025 | Crypto 101 Media (Ad)INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial DangersDecember 30, 2024 | seekingalpha.comINmune Bio Inc. Completes Repayment of Silicon Valley Bank DebtDecember 10, 2024 | markets.businessinsider.comOmniScience and INmune Bio Partner for Alzheimer’s TrialDecember 5, 2024 | finance.yahoo.comSee More INmune Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like INmune Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on INmune Bio and other key companies, straight to your email. Email Address About INmune BioINmune Bio (NASDAQ:INMB), a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.View INmune Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Infosys (1/16/2025)Bank of America (1/16/2025)U.S. Bancorp (1/16/2025)Morgan Stanley (1/16/2025)The PNC Financial Services Group (1/16/2025)Taiwan Semiconductor Manufacturing (1/16/2025)UnitedHealth Group (1/16/2025)Schlumberger (1/17/2025)Truist Financial (1/17/2025)Netflix (1/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
